Biogen's earnings beat could positively impact investor sentiment due to the higher than expected EPS, indicating operational efficiency and profitability. However, the miss on sales forecasts could temper enthusiasm, reflecting potential challenges in revenue growth. The mixed results present a neutral short-term outlook for BIIB's stock price, as the positive earnings surprise is offset by the slight disappointment in sales.